Nabsys

The Brown University spinout plans to market its instrument, Nabsys HD-Mapping, for genome mapping, de novo assembly, and structural variant detection. 

At a workshop organized by the Genome in a Bottle consortium last month, Nabsys presented its human genome maps for the first time.

After closing its doors last September, Nabsys has resumed operations, refocusing on its core technology.

2.0 Time

Former CEO Barrett Bready has purchased the recently shuttered Nabsys for $500,000 and the assumption of $100,000 in debt, according to GoLocalProv.

According to local news reports, the company recently closed its facility in Providence, Rhode Island.

Nabsys CEO Steve Lombardi and CSO Tony Shuber spoke with GenomeWeb at last week's JP Morgan conference in San Francisco. 

The companies will combine Nabsys' technology to identify the structural variants with Ariana's clinical data analysis tools.

NabSys has been awarded

This article was originally published Nov. 3.
NEW YORK (GenomeWeb) – Following the recent appointments of a new CEO and CSO, Nabsys is shifting its strategy toward developing a platform for clinical applications, in particular structural variation analysis of cancer genomes.

Quest Diagnostics has elected Jeffrey Leiden to its Board of Directors. Leiden is the chairman, president, and CEO of Vertex Pharmaceuticals.

Pages

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.